ReviewFrontiers in pharmacology2026
Host-directed therapeutics against antimicrobial-resistant bacterial infections: emerging roles of multi-omics and systems biology.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid emergence and global dissemination of antimicrobial resistance (AMR), coupled with the limited development of new antimicrobial agents, have intensified concerns regarding a major global public health crisis. Although antibiotic resistance is primarily driven by microbial mechanisms, host immune and inflammatory responses also play critical roles in determining infection outcomes, pathogen persistence, and treatment efficacy. In this context, host-directed therapies (HDTs) have emerged as a promising complementary strategy by modulating host pathways to enhance antimicrobial immunity, improve bacterial clearance, reduce tissue damage, and restore antibiotic efficacy against multidrug-resistant (MDR) pathogens. Unlike conventional antibiotics, HDTs target conserved host processes, thereby reducing the selective pressure for the emergence of resistance. Recent advances in multi-omics technologies, including genomics, transcriptomics, proteomics, metabolomics, and epigenomics, combined with systems biology approaches, have greatly improved our understanding of host-pathogen interactions during bacterial infections, including those caused by antimicrobial-resistant pathogens. These approaches facilitate the identification of resistance-associated host pathways, molecular networks, and therapeutic targets, while high-throughput screening and computational modelling accelerate the discovery and validation of host-directed interventions. This review highlights emerging host-directed therapeutic strategies against antimicrobial-resistant bacterial infections, with particular emphasis on the use of multi-omics and systems biology to identify and validate host targets associated with resistance phenotypes. We also discuss current approaches to modulate host immune and inflammatory responses, summarize recent advances in host-targeted interventions, and outline the challenges and prospects for translating HDTs into clinical practice to combat AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.